Cargando…
Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial
BACKGROUND: Antenatal vitamin D status may be associated with the risk of adverse pregnancy and neonatal outcomes; however, the benefits of vitamin D supplementation during pregnancy remain unknown. METHODS: We conducted a double-blind placebo-controlled randomized trial to evaluate the effect of hi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641012/ https://www.ncbi.nlm.nih.gov/pubmed/23587190 http://dx.doi.org/10.1186/1475-2891-12-47 |
_version_ | 1782267962514735104 |
---|---|
author | Roth, Daniel E Al Mahmud, Abdullah Raqib, Rubhana Akhtar, Evana Perumal, Nandita Pezzack, Brendon Baqui, Abdullah H |
author_facet | Roth, Daniel E Al Mahmud, Abdullah Raqib, Rubhana Akhtar, Evana Perumal, Nandita Pezzack, Brendon Baqui, Abdullah H |
author_sort | Roth, Daniel E |
collection | PubMed |
description | BACKGROUND: Antenatal vitamin D status may be associated with the risk of adverse pregnancy and neonatal outcomes; however, the benefits of vitamin D supplementation during pregnancy remain unknown. METHODS: We conducted a double-blind placebo-controlled randomized trial to evaluate the effect of high-dose prenatal 3(rd) trimester vitamin D3 supplementation on maternal and neonatal (cord blood) serum 25-hydroxyvitamin D (25(OH)D) concentration (primary biochemical efficacy outcome) and maternal serum calcium concentration (primary safety measure). Eligibility criteria were pregnant women aged 18 to <35 years, at 26 to 29 weeks gestation, and residing in Dhaka, Bangladesh. 160 women were randomized by 1:1 allocation to one of two parallel intervention groups; placebo (n = 80) or 35,000 IU/week of vitamin D3 (n = 80) until delivery. All participants, study personnel and study investigators were blind to treatment allocation. RESULTS: Mean maternal 25(OH)D concentration was similar in the vitamin D and placebo groups at baseline (45 vs. 44 nmol/L; p = 0.66), but was significantly higher in the vitamin D group vs. placebo group among mothers at delivery (134 vs. 38 nmol/L; p < 0.001) and newborns (cord blood: 103 vs. 39; p < 0.001). In the vitamin D group, 95% of neonates and 100% of mothers attained 25(OH)D >50 nmol/L, versus 21% mothers and 19% of neonates in the placebo group. No participants met criteria for hypercalcemia, there were no known supplement-related adverse events, and major pregnancy outcomes were similar between groups. CONCLUSIONS: Antenatal 3(rd)-trimester vitamin D3 supplementation (35,000 IU/week) significantly raised maternal and cord serum 25(OH)D concentrations above 50 nmol/L in almost all participants without inducing hypercalcemia or other observed safety concerns. Doses up to 35,000 IU/week may be cautiously used in further research aimed at establishing the clinical effects and safety of vitamin D3 supplementation in pregnancy. TRIAL REGISTRATION: This trial was registered at ClinicalTrials.gov (NCT01126528). |
format | Online Article Text |
id | pubmed-3641012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36410122013-05-02 Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial Roth, Daniel E Al Mahmud, Abdullah Raqib, Rubhana Akhtar, Evana Perumal, Nandita Pezzack, Brendon Baqui, Abdullah H Nutr J Research BACKGROUND: Antenatal vitamin D status may be associated with the risk of adverse pregnancy and neonatal outcomes; however, the benefits of vitamin D supplementation during pregnancy remain unknown. METHODS: We conducted a double-blind placebo-controlled randomized trial to evaluate the effect of high-dose prenatal 3(rd) trimester vitamin D3 supplementation on maternal and neonatal (cord blood) serum 25-hydroxyvitamin D (25(OH)D) concentration (primary biochemical efficacy outcome) and maternal serum calcium concentration (primary safety measure). Eligibility criteria were pregnant women aged 18 to <35 years, at 26 to 29 weeks gestation, and residing in Dhaka, Bangladesh. 160 women were randomized by 1:1 allocation to one of two parallel intervention groups; placebo (n = 80) or 35,000 IU/week of vitamin D3 (n = 80) until delivery. All participants, study personnel and study investigators were blind to treatment allocation. RESULTS: Mean maternal 25(OH)D concentration was similar in the vitamin D and placebo groups at baseline (45 vs. 44 nmol/L; p = 0.66), but was significantly higher in the vitamin D group vs. placebo group among mothers at delivery (134 vs. 38 nmol/L; p < 0.001) and newborns (cord blood: 103 vs. 39; p < 0.001). In the vitamin D group, 95% of neonates and 100% of mothers attained 25(OH)D >50 nmol/L, versus 21% mothers and 19% of neonates in the placebo group. No participants met criteria for hypercalcemia, there were no known supplement-related adverse events, and major pregnancy outcomes were similar between groups. CONCLUSIONS: Antenatal 3(rd)-trimester vitamin D3 supplementation (35,000 IU/week) significantly raised maternal and cord serum 25(OH)D concentrations above 50 nmol/L in almost all participants without inducing hypercalcemia or other observed safety concerns. Doses up to 35,000 IU/week may be cautiously used in further research aimed at establishing the clinical effects and safety of vitamin D3 supplementation in pregnancy. TRIAL REGISTRATION: This trial was registered at ClinicalTrials.gov (NCT01126528). BioMed Central 2013-04-12 /pmc/articles/PMC3641012/ /pubmed/23587190 http://dx.doi.org/10.1186/1475-2891-12-47 Text en Copyright © 2013 Roth et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Roth, Daniel E Al Mahmud, Abdullah Raqib, Rubhana Akhtar, Evana Perumal, Nandita Pezzack, Brendon Baqui, Abdullah H Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial |
title | Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial |
title_full | Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial |
title_fullStr | Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial |
title_full_unstemmed | Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial |
title_short | Randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin D3 supplementation in Bangladesh: the AViDD trial |
title_sort | randomized placebo-controlled trial of high-dose prenatal third-trimester vitamin d3 supplementation in bangladesh: the avidd trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641012/ https://www.ncbi.nlm.nih.gov/pubmed/23587190 http://dx.doi.org/10.1186/1475-2891-12-47 |
work_keys_str_mv | AT rothdaniele randomizedplacebocontrolledtrialofhighdoseprenatalthirdtrimestervitamind3supplementationinbangladeshtheaviddtrial AT almahmudabdullah randomizedplacebocontrolledtrialofhighdoseprenatalthirdtrimestervitamind3supplementationinbangladeshtheaviddtrial AT raqibrubhana randomizedplacebocontrolledtrialofhighdoseprenatalthirdtrimestervitamind3supplementationinbangladeshtheaviddtrial AT akhtarevana randomizedplacebocontrolledtrialofhighdoseprenatalthirdtrimestervitamind3supplementationinbangladeshtheaviddtrial AT perumalnandita randomizedplacebocontrolledtrialofhighdoseprenatalthirdtrimestervitamind3supplementationinbangladeshtheaviddtrial AT pezzackbrendon randomizedplacebocontrolledtrialofhighdoseprenatalthirdtrimestervitamind3supplementationinbangladeshtheaviddtrial AT baquiabdullahh randomizedplacebocontrolledtrialofhighdoseprenatalthirdtrimestervitamind3supplementationinbangladeshtheaviddtrial |